BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Plexpress Expands Range of Pre-Validated Probes for ADME-Tox Studies


8/28/2012 10:26:58 AM

HELSINKI, FINLAND, 28 Aug 2012: Plexpress, creator of the innovative TRAC (Transcript Analysis with the aid of Affinity Capture) platform, has recently added to its growing library of pre-validated probes for multiplexed gene expression analysis. This includes many genes relevant for the investigation of in vitro drug interactions during pre-clinical studies, such as key members of the Cytochrome P450 family and many membranous transport channels. Researchers can now select from hundreds of genes and carry out reliable, accurate and cost-effective ADME-Tox studies in a range of model systems, including human hepatocytes and rat liver tissue, with high sample throughput. While the pre-validated panels are perfect for ‘off-the-shelf’ use, the TRAC system can also be set-up and optimized for any gene where the sequence is known, providing researchers with the flexibility to investigate any gene combination using both novel and pre-validated probes.

Jari Rautio, Ph.D., CEO of Plexpress, commented: “TRAC is ideal for ADME-Tox studies as it allows the rapid analysis of an investigational drug in many thousands of samples, without sacrificing the number of genes being analyzed. New compounds likely to be toxic or ineffective can therefore be identified early in the process, before costly clinical trials have taken place.” The use of gene expression to analyze ADME-Tox profiles is widespread in drug discovery, a trend that is likely to continue given a recent draft from report from the FDA suggesting that drug discovery researchers use CYP mRNA induction, rather than CYP activity, to assess drug metabolism and activity (1). Dr Rautio continued: “The TRAC approach has already proved very popular with Biotech, Pharma and Contract Research Organizations, as it offers significant accuracy, speed and cost benefits over more traditional targeted approaches such as qPCR. To-date TRAC been used by over 100 studies to investigate gene expression in a range of experimental systems.”

TRAC uses 96 well plates and avoids the need for RNA extraction, cDNA conversion and amplification, reducing experimental bias. It can also multiplex up to 30 genes per sample, providing expression profiles for all key genes in a single, fast experiment, while minimizing technical variation. The Plexpress Human ADME-Tox panels can feature up to 6 reference genes and numerous targets including 14 CYP450 genes, glucuronosyl transferases, glutathione transferases and ABC transporters. The Plexpress rat ADME-Tox library has over 14 reference genes and more than 120 targets to choose from including hepatotoxicity, necrosis, cholestasis and steatosis markers as well as those associated with drug metabolism and transport pathways.

Depending on the needs of each project, Plexpress can process user’s samples via its ISO9001 certified FAST TRAC gene expression service or assist with setting up TRAC in a user’s own laboratory. TRAC is compatible with most third party magnetic bead processors and capillary electrophoresis devices. Plexpress also offers a ‘one-stop-shop’ for studies requiring fully integrated gene discovery, validation and in-depth analysis. The OneTRAC™ service, offered in collaboration with the Phalanx Biotech Group, combines the coverage breadth of Phalanx Biotech’s OneArray® microarrays with the high-throughput, multiplex capabilities of targeted TRAC analysis, allowing researchers to identify, select and validate a robust set of highly-relevant gene expression signatures. As well as its application in biomarker development, the OneTRAC™ service is fully capable of addressing the diverse needs of academic research projects and drug discovery programs alike.

For more information on the benefits offered by TRAC gene expression analysis, please visit the Plexpress website at www.plexpress.com.

Reference:

1. FDA Guidance for Industry Report (Feb 2012): Drug Interaction Studies Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations

About Plexpress

Plexpress was established as a spinoff from the Finnish Technology Research Center VTT in 2007. Including R&D at VTT, the company’s TRAC technology has been developed continuously for nearly 10 years and it has been documented in over 15 publications. The technology was originally developed for demanding bioprocess applications, which required a very robust solution for gene expression analysis. Since starting operations in 2008, the company has carried out over 50 projects using the TRAC technology in the fields of pharmaceutical development and academic research.

For further information see: www.plexpress.com


Read at BioSpace.com

Plexpress
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->